• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间质-上皮转化的机制及其与转移性肿瘤形成的关系。

Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation.

机构信息

Department of Hepatobiliary and Splenic Surgery, Shengjing Hospital of China Medical University, Heping District, Shenyang 110004, Liaoning Province, China.

出版信息

Mol Cancer Res. 2011 Dec;9(12):1608-20. doi: 10.1158/1541-7786.MCR-10-0568. Epub 2011 Aug 12.

DOI:10.1158/1541-7786.MCR-10-0568
PMID:21840933
Abstract

Cancer metastasis consists of a sequential series of events, and the epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are recognized as critical events for metastasis of carcinomas. A current area of focus is the histopathological similarity between primary and metastatic tumors, and MET at sites of metastases has been postulated to be part of the process of metastatic tumor formation. Here, we summarize accumulating evidence from experimental studies that directly supports the role of MET in cancer metastasis, and we analyze the main mechanisms that regulate MET or reverse EMT in carcinomas. Given the critical role of MET in metastatic tumor formation, the potential to effectively target the MET process at sites of metastasis offers new hope for inhibiting metastatic tumor formation.

摘要

癌症转移由一系列连续事件组成,上皮-间充质转化 (EMT) 和间充质-上皮转化 (MET) 被认为是癌转移的关键事件。目前的一个关注领域是原发性和转移性肿瘤之间的组织病理学相似性,并且已经推测转移部位的 MET 是转移性肿瘤形成过程的一部分。在这里,我们总结了来自实验研究的越来越多的证据,这些证据直接支持 MET 在癌症转移中的作用,并分析了调节癌中 MET 或逆转 EMT 的主要机制。鉴于 MET 在转移性肿瘤形成中的关键作用,有效靶向转移部位的 MET 过程为抑制转移性肿瘤形成提供了新的希望。

相似文献

1
Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation.间质-上皮转化的机制及其与转移性肿瘤形成的关系。
Mol Cancer Res. 2011 Dec;9(12):1608-20. doi: 10.1158/1541-7786.MCR-10-0568. Epub 2011 Aug 12.
2
EMT as the ultimate survival mechanism of cancer cells.癌细胞的终极生存机制 EMT。
Semin Cancer Biol. 2012 Jun;22(3):194-207. doi: 10.1016/j.semcancer.2012.02.013. Epub 2012 Mar 8.
3
Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis.通过上皮-间质转化介导脑转移的分子途径:基因、蛋白质及功能分析
Anticancer Res. 2016 Feb;36(2):523-32.
4
Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells.miR-429 的过表达诱导转移性卵巢癌细胞中的间充质-上皮转化(MET)。
Gynecol Oncol. 2011 Apr;121(1):200-5. doi: 10.1016/j.ygyno.2010.12.339. Epub 2011 Jan 28.
5
Growth factors in induction of epithelial-mesenchymal transition and metastasis.生长因子在诱导上皮-间充质转化和转移中的作用。
Cells Tissues Organs. 2011;193(1-2):85-97. doi: 10.1159/000320360. Epub 2010 Nov 3.
6
Concepts of metastasis in flux: the stromal progression model.转移概念的转变:基质演进模型。
Semin Cancer Biol. 2012 Jun;22(3):174-86. doi: 10.1016/j.semcancer.2012.02.007. Epub 2012 Feb 21.
7
MicroRNAs in colorectal cancer metastasis.结直肠癌转移中的 microRNAs。
J Pathol. 2011 Aug;224(4):438-47. doi: 10.1002/path.2922. Epub 2011 Jun 27.
8
Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis.上皮-间质转化和癌症转移的表观遗传控制。
Exp Cell Res. 2013 Jan 15;319(2):160-9. doi: 10.1016/j.yexcr.2012.07.019. Epub 2012 Aug 1.
9
[Encounter of cancer cells with bone. The significance of cancer stem cells and epithelial-mesenchymal transition in tumor invasion and metastasis].[癌细胞与骨的相遇。癌症干细胞和上皮-间质转化在肿瘤侵袭和转移中的意义]
Clin Calcium. 2011 Mar;21(3):411-7.
10
Non-coding RNAs regulate tumor cell plasticity.非编码 RNA 调控肿瘤细胞可塑性。
Sci China Life Sci. 2013 Oct;56(10):886-90. doi: 10.1007/s11427-013-4554-5. Epub 2013 Oct 5.

引用本文的文献

1
HSF2 drives breast cancer progression by acting as a stage-specific switch between proliferation and invasion.热休克因子2通过在增殖和侵袭之间充当阶段特异性开关来驱动乳腺癌进展。
Sci Adv. 2025 Sep 5;11(36):eady1289. doi: 10.1126/sciadv.ady1289. Epub 2025 Sep 3.
2
New Vistas in Infection and Its Association with Lung Cancer Development.感染及其与肺癌发生关联的新视角
Cancers (Basel). 2025 Jul 2;17(13):2224. doi: 10.3390/cancers17132224.
3
The Evolving Landscape of GEP-NENs in the Era of Precision Oncology: Molecular Insights into Tumor Heterogeneity.
精准肿瘤学时代GEP-NENs的演变格局:对肿瘤异质性的分子见解
Cancers (Basel). 2025 Jun 21;17(13):2080. doi: 10.3390/cancers17132080.
4
miR‑145 and miR‑23b co‑transfection decreases proliferation, migration, invasion and protein levels of c‑MYC, ZEB1 and ABCB1 in epithelial ovarian cancer cell lines.miR-145和miR-23b共转染可降低上皮性卵巢癌细胞系中c-MYC、ZEB1和ABCB1的增殖、迁移、侵袭及蛋白水平。
Mol Med Rep. 2025 Sep;32(3). doi: 10.3892/mmr.2025.13611. Epub 2025 Jul 11.
5
Unraveling the Hippo pathway: YAP/TAZ as central players in cancer metastasis and drug resistance.解析河马通路:YAP/TAZ在癌症转移和耐药性中扮演核心角色。
EXCLI J. 2025 Jun 6;24:612-637. doi: 10.17179/excli2025-8351. eCollection 2025.
6
Role of Mesenchymal Markers in Colorectal Cancer Metastasis.间充质标志物在结直肠癌转移中的作用
Mol Biol Rep. 2025 Jul 4;52(1):673. doi: 10.1007/s11033-025-10745-3.
7
Connexin43 functions as a non-canonical phenotypic stability factor in promoting hybrid Epithelial/Mesenchymal phenotype in glioblastoma cells.连接蛋白43作为一种非典型表型稳定性因子,在促进胶质母细胞瘤细胞的上皮/间充质混合表型中发挥作用。
Transl Oncol. 2025 Jun 30;59:102463. doi: 10.1016/j.tranon.2025.102463.
8
ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer.ESRP1通过促进弥漫型胃癌中的铁死亡发挥抗肿瘤作用。
J Exp Clin Cancer Res. 2025 Jun 18;44(1):176. doi: 10.1186/s13046-025-03435-2.
9
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma.在输卵管卵巢高级别浆液性癌小鼠模型中,将细胞周期蛋白依赖性激酶12(CDK12)定义为一种肿瘤抑制因子和治疗靶点。
Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2426909122. doi: 10.1073/pnas.2426909122. Epub 2025 Jun 12.
10
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.BRCA1和BRCA2相关乳腺癌的新辅助聚(ADP-核糖)聚合酶抑制剂给药方案:PARTNER,一项随机II/III期试验。
Nat Commun. 2025 May 13;16(1):4269. doi: 10.1038/s41467-025-59151-0.